HDL Therapeutics
Manufacturing · Florida, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
601 21st St Ste 300, Vero Beach, Florida...Phone Number
(772) 453-2770Website
www.hdltherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About HDL Therapeutics
HDL Therapeutics, Inc. is pioneering innovative treatments for atherosclerosis, focusing on improving disease management and treatment for patients. Their flagship product, the PDS-2 System, is the only FDA-approved therapy that utilizes HDL (good cholesterol) to reduce coronary artery plaques in patients with Homozygous Familial Hypercholesterolemia (HoFH). The company is led by a team of experts with extensive experience in the pharmaceutical, biotechnology, and medical device sectors. HDL Therapeutics aims to transform the landscape of atherosclerosis treatment through their novel approach.Explore more
HDL Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is HDL Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
HDL Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if HDL Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once HDL Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at HDL Therapeutics
Product Launch: Get notified when HDL Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if HDL Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Click to see if HDL Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on HDL Therapeutics recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined HDL Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to HDL Therapeutics
Compare insights from companies similar to HDL Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
HDL Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
HDL Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about HDL Therapeutics.
HDL Therapeutics financials insights
Gather financial insights about HDL Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Series A
$925K
2014
Series B
$2M
2016
Series C
$1.5M
HDL Therapeutics Tech Stack
A closer look at the technologies used by HDL Therapeutics
See more technologies
HDL Therapeutics News & Media
HDL Therapeutics to Go Public in Merger with Swiftmerge Acquisition Corp.
NEW YORK & VERO BEACH, Fla.--(BUSINESS WIRE)---- $ipo #Consumer--HDL Therapeutics, Inc. (“HDL Therapeutics”), a privately held commercial stage biotech company with an FDA-approved cardiovascular therapy the Plasma Delipidation System (PDS-2™ System) for reducing coronary atheroma in patients with homozygous familial hypercholesterolemia (HoFH), has signed a definitive merger agreement with Swiftmerge Acquisition Corp. (NASDAQ: IVCP) (“Swiftmerge”), a special purpose acquisition company with a dHDL Therapeutics Inc Plans to Become Publicly Traded via a Business Combination With $225 Million Swiftmerge (NASDAQ: IVCP) With Goal to Transform Cardiovascular Disease Treatment
NEW YORK & VERO BEACH, Fla.--(BUSINESS WIRE)---- $health #Consumer--NASDAQ IVCP Swiftmerge Acquisition Corp (“Swiftmerge”), a $225 million innovative healthcare investment corporation and a special purpose acquisition company, announced today the signing of a non-binding letter of intent (“LOI”) for a business combination with HDL Therapeutics Inc. (“HDL Therapeutics”), a privately held commercial stage biotech company with an FDA-approved cardiovascular therapy for reducing coronary atheroma inHDL Therapeutics Announces Positive Data From Registration Trial of PDS-2™ System in Homozygous Familial Hypercholesterolemia
VERO BEACH, Fla., May 15, 2019 /PRNewswire/ -- HDL Therapeutics, a clinical stage company and an emerging leader in the field of reversing coronary atherosclerosis, today announced positive data from the company's registrational trial for its investigational acute care therapeutic device, ...
Read more news
Top Manufacturing Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding HDL Therapeutics
Sign Up For FreeTo access detailed company insights
HDL Therapeutics, Inc. is pioneering innovative treatments for atherosclerosis, focusing on improving disease management and treatment for patients. Their flagship product, the PDS-2 System, is the only FDA-approved therapy that utilizes HDL (good cholesterol) to reduce coronary artery plaques in patients with Homozygous Familial Hypercholesterolem... Read More
